Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists

Multiple Sclerosis

Volumn 16, Issue 12, 2010, Pages 1507-1512

  Heesen, Christoph ^a   Kleiter, Ingo ^b   Nguyen, Franziska ^a   Schäffler, Nina ^a   Kasper, Jürgen ^a   Köpke, Sascha ^c   Gaissmaier, Wolfgang ^d  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c UNIVERSITY OF HAMBURG   (Germany)

^d MAX PLANCK INSTITUTE FOR HUMAN DEVELOPMENT   (Germany)

Author keywords

multiple sclerosis; natalizumab; progressive multifocal leukoencephalopathy; risk perception; shared decision making

Indexed keywords

NATALIZUMAB;

ADULT; ARTICLE; ATTITUDE; DECISION MAKING; DISEASE COURSE; DISEASE DURATION; DRUG INFORMATION; EVIDENCE BASED PRACTICE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PERCEPTION; PRIVATE PRACTICE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; IMMUNOLOGIC FACTORS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PATIENTS; PERCEPTION; PHYSICIAN-PATIENT RELATIONS; PHYSICIANS; RISK;

EID: 78650123808     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510379819     Document Type: Article

References (21)

1. Filippini G., Munari L., Incorvaia B., Ebers GC, Polman C., D'Amico R., et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003 ; 361: 545-552. (Pubitemid 36207471)
2. Whiting P., Harbord R., Main C., Deeks JJ, Filippini G., Egger M., et al. Accuracy of magnetic resonance imaging for the diagnosis of multiple sclerosis: systematic review. BMJ 2006 ; 332: 875-884.
3. Heesen C., Kasper J., Kopke S., Richter T., Segal J. and Muhlhauser I. Informed shared decision making in multiple sclerosis - inevitable or impossible? J Neurol Sci 2007 ; 259: 109-117. (Pubitemid 47033934)
4. Rothwell PM, McDowell Z., Wong CK and Dorman PJ Doctors and patients don't agree: cross-sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ 1997 ; 314: 1580-1583.
5. Heesen C., Kolbeck J., Gold SM, Schulz H. and Schulz KH Delivering the diagnosis of MS - results of a survey among patients and neurologists. Acta Neurol Scand 2003 ; 107: 363-368.
6. Kasper J., Kopke S., Muhlhauser I. and Heesen C. Evidence-based patient information about treatment of multiple sclerosis - a phase one study on comprehension and emotional responses. Patient Educ Couns 2006 ; 62: 56-63.
7. O'Connor AM, Wennberg JE, Legare F., Llewellyn-Thomas HA, Moulton BW, Sepucha KR, et al. Toward the 'tipping point': decision aids and informed patient choice. Health Aff (Millwood) 2007 ; 26: 716-725.
8. Polman CH, O'Connor PW, Havrdova E., Hutchinson M., Kappos L., Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 ; 354: 899-910.
9. Rudick RA, Stuart WH, Calabresi PA, Confavreux C., Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006 ; 354: 911-923.
10. Major EO Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010 ; 61: 35-47.
11. PML Inzidenz [online]. Available at: http://tysabri.de/index.php?inhalt= tysabri.pmlinzidenz. (accessed June 2010 ).
12. Gold R., Hartung H., Hohlfeld R., et al. Therapy of multiple sclerosis with monoclonal antibodies. Results and recommendations of a Symposium of the Medical Advisory Board of the German MS Society. Aktuelle Neurologie 2009 ; 36: 334-344.
13. Gigerenzer G., Gaissmaier W., Kurz-Milcke E., Schwartz L. and Woloshins S. Helping doctors and patients make sense of health statistics. Psychol Sci Public Interest 2007 ; 8: 53-96.
14. Bunge M., Muhlhauser I. and Steckelberg A. What constitutes evidence-based patient information? Overview of discussed criteria. Patient Educ Couns 2010 ; 78: 316-328.
15. GMC 'Consent: patients and doctors making decisions together', Available at: http://www.gmc-uk.org/static/documents/content/Consent-2008.pdf (accessed January 2010 ).
16. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 ; 33: 1444-1452.
17. Schwartz LM, Woloshin S. and Welch HG Can patients interpret health information? An assessment of the medical data interpretation test. Med Decis Making 2005 ; 25: 290-300.
18. Boeije HR and Janssens Acjw. 'It might happen or it might not': how patients with multiple sclerosis explain their perception of prognostic risk. Soc Sci Med 2004 ; 59: 861-868.
19. Johnson FR, Ozdemir S., Mansfield C., Hass S., Miller DW, Siegel CA, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 2007 ; 133: 769-779.
20. Shaffer V. and Hulsey L. Are patient decision aids effective? Insight from revisiting the debate between correspondence and coherence theories of judgment. Judgment Decis Mak 2009 ; 4: 141-146.
21. Hauser SL and Johnston SC Balancing risk and reward: the question of natalizumab. Ann Neurol 2009 ; 66: A7 - A8. stion of natalizumab. Ann Neurol 2009 ; 66: A7 - A8.